Published in J Immunol on May 15, 2009
Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol (2013) 1.53
Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol (2011) 1.04
Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano (2014) 0.97
The role of regulatory T cells in cancer. Immune Netw (2009) 0.93
5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm (2014) 0.89
Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. J Vet Intern Med (2010) 0.86
Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy. Int J Mol Sci (2014) 0.84
Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation. Mol Ther (2009) 0.81
Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Mol Ther (2011) 0.81
Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells. Exp Ther Med (2011) 0.80
Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. Oncoimmunology (2014) 0.80
Resveratrol analogue HS-1793 induces the modulation of tumor-derived T cells. Exp Ther Med (2012) 0.79
Increased P-35, EBI3 Transcripts and Other Treg Markers in Peripheral Blood Mononuclear Cells of Breast Cancer Patients with Different clinical Stages. Adv Pharm Bull (2015) 0.79
The roles of antigen-specificity, responsiveness to transforming growth factor-β and antigen-presenting cell subsets in tumour-induced expansion of regulatory T cells. Immunology (2010) 0.78
Depletion of phagocytic myeloid cells triggers spontaneous T cell- and NK cell-dependent antitumor activity. Oncoimmunology (2012) 0.77
Astrocytes inhibit microglial surface expression of dendritic cell-related co-stimulatory molecules through a contact-mediated process. J Neurochem (2013) 0.77
Immune modulation of CD4(+)CD25(+) regulatory T cells by zoledronic acid. BMC Immunol (2016) 0.75
How to detour Treg cells in T cell-based antitumor immune therapy. Onco Targets Ther (2013) 0.75
Transplanted tumor growth and the incidence of T-lymphocyte populations in the spleen of newcastle virus-treated mice. Cancer Biother Radiopharm (2015) 0.75
Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma. Oncotarget (2016) 0.75
Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4(+) T cells combined with agonist α-GITR mAb promotes durable CD8(+) T-cell-dependent antitumor immunity. Oncoimmunology (2017) 0.75
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol (2002) 12.73
CTLA-4 control over Foxp3+ regulatory T cell function. Science (2008) 12.67
How regulatory T cells work. Nat Rev Immunol (2008) 11.66
Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol (2007) 6.94
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Mechanisms of suppression by suppressor T cells. Nat Immunol (2005) 5.52
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol (2004) 4.62
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A (2003) 4.18
CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol (2000) 3.63
Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J Exp Med (2006) 3.57
Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A (2008) 3.40
Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity (2007) 3.33
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity (2008) 2.97
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res (2007) 2.57
Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol (2004) 2.56
Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. Blood (2005) 2.55
Regulatory T cells and treatment of cancer. Curr Opin Immunol (2008) 2.01
Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res (2006) 1.97
CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity (2008) 1.95
Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol (2008) 1.83
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol (2009) 1.64
The tumor-draining lymph node as an immune-privileged site. Immunol Rev (2006) 1.57
Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother (2006) 1.53
CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol (2007) 1.48
CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother (2006) 1.47
Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur J Immunol (2007) 1.45
Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res (2006) 1.39
IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol (2008) 1.34
Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells. J Immunol (2007) 1.33
Modulation of dendritic cell function by naive and regulatory CD4+ T cells. J Immunol (2006) 1.31
Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol (2006) 1.29
Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol (2005) 1.18
Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol (2007) 1.14
Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol (2007) 1.14
Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol (2007) 1.11
Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther (2005) 1.06
Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing. J Immunol (2008) 1.04
Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells. J Immunol (2008) 1.03
CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J Clin Invest (2008) 1.01
Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J Immunol (2008) 0.98
Anti-CD4-mediated selection of Treg in vitro - in vitro suppression does not predict in vivo capacity to prevent graft rejection. Eur J Immunol (2008) 0.95
Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood (2004) 3.68
Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood (2002) 2.02
Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol (2005) 1.97
Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity (2006) 1.95
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol (2007) 1.60
CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells. J Immunol (2005) 1.52
Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood (2013) 1.48
Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol (2005) 1.39
Changing paradigms in cutaneous immunology: adapting with dendritic cells. J Invest Dermatol (2005) 1.35
Association between BMI and metabolic syndrome and adenomatous colonic polyps in Korean men. Obesity (Silver Spring) (2008) 1.25
Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis. J Cell Biol (2003) 1.13
Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther (2005) 1.06
Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol (2011) 1.04
Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res (2005) 1.04
Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther (2005) 1.04
Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells. J Immunol (2008) 1.03
Verification by polymerase chain reaction of vertical transmission of Theileria sergenti in cows. Can J Vet Res (2003) 0.97
Lentivirus as a potent and mechanistically distinct vector for genetic immunization. Curr Opin Mol Ther (2007) 0.97
Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol (2006) 0.96
IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. J Immunother (2009) 0.92
Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res (2007) 0.92
Disrupted homeostasis of Langerhans cells and interdigitating dendritic cells in monkeys with AIDS. Blood (2002) 0.90
Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. Expert Rev Vaccines (2007) 0.90
Resistance of Sézary cells to TNF-α-induced apoptosis is mediated in part by a loss of TNFR1 and a high level of the IER3 expression. Exp Dermatol (2012) 0.89
Phagocytosis induces lysosome remodeling and regulated presentation of particulate antigens by activated dendritic cells. J Immunol (2006) 0.88
DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine (2004) 0.85
Vaccination with photodynamic therapy-treated macrophages induces highly suppressive T-regulatory cells. Photodermatol Photoimmunol Photomed (2011) 0.85
Role of infectious agents in cutaneous T-cell lymphoma: facts and controversies. Clin Dermatol (2013) 0.84
Comparative proteomic analysis reveals unique tumor protein composition among the melanoma subtypes pure desmoplastic and superficial spreading. Melanoma Res (2014) 0.84
Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Exp Cell Res (2003) 0.83
Highly efficient expression of transgenic proteins by naked DNA-transfected dendritic cells through terminal differentiation. Blood (2003) 0.83
Low extracellular pH augments TRAIL-induced apoptotic death through the mitochondria-mediated caspase signal transduction pathway. Exp Cell Res (2004) 0.82
Reconstitution of caspase-3 confers low glucose-enhanced tumor necrosis factor-related apoptosis-inducing ligand cytotoxicity and Akt cleavage. Clin Cancer Res (2004) 0.81
Dissolvable microneedle arrays for intradermal delivery of biologics: fabrication and application. Pharm Res (2013) 0.81
Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Arch Dermatol (2008) 0.81
Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation. Mol Ther (2009) 0.81
Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther (2003) 0.81
Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity. J Control Release (2013) 0.81
Interaction effect of serum 25-hydroxyvitamin D levels and CYP1A1, CYP1B1 polymorphisms on blood pressure in an elderly population. J Hypertens (2015) 0.81
Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Mol Ther (2011) 0.81
Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector. Immunol Res (2006) 0.80
Human beta-defensin 3 induces maturation of human langerhans cell-like dendritic cells: an antimicrobial peptide that functions as an endogenous adjuvant. J Invest Dermatol (2012) 0.80
Enhancement of metabolic oxidative stress-induced cytotoxicity by the thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide is mediated through the ASK1-SEK1-JNK1 pathway. Mol Pharmacol (2002) 0.79
A 'good death' for tumor immunology. Nat Med (2007) 0.79
Human cytomegalovirus induces apoptosis in promonocyte THP-1 cells but not in promyeloid HL-60 cells. Virus Res (2003) 0.76
Novel therapeutic combination demonstrates more than additive effects in cutaneous T-cell lymphoma. Leuk Lymphoma (2015) 0.75
Utilization of hierarchical, stochastic relationship modeling for Hangul character recognition. IEEE Trans Pattern Anal Mach Intell (2004) 0.75
A Fast Finite-Time Neural Network Control of Stochastic Nonlinear Systems. IEEE Trans Neural Netw Learn Syst (2022) 0.75
Effects of personality traits on collaborative performance in problem-based learning tutorials. Saudi Med J (2017) 0.75
High performing smart electrochromic device based on honeycomb nanostructured h-WO3 thin films: hydrothermal assisted synthesis. Dalton Trans (2015) 0.75
Quantitative correlation between infectivity and Gp120 density on HIV-1 virions revealed by optical trapping virometry. J Biol Chem (2017) 0.75